Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TRVI Trevi Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TRVI
Price (delayed)
$6.09
Market cap
$619.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.45
Enterprise value
$601.21M
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation
Highlights
Trevi Therapeutics's quick ratio has increased by 47% QoQ and by 9% YoY
The equity rose by 37% year-on-year
The EPS has decreased by 32% YoY but it has increased by 4.3% QoQ
Trevi Therapeutics's net income has decreased by 41% YoY
Key stats
What are the main financial stats of TRVI
Market
Valuations
Earnings
Shares outstanding
101.74M
Market cap
$619.63M
Enterprise value
$601.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$51.09M
Net income
-$47.35M
EBIT
-$47.38M
EBITDA
-$47.23M
Free cash flow
-$41.3M
Per share
Balance sheet
Liquidity
EPS
-$0.45
EPS diluted
-$0.45
Free cash flow per share
-$0.35
Book value per share
$1.03
Revenue per share
$0
TBVPS
$0.91
Total assets
$107M
Total liabilities
$7.55M
Debt
$957,000
Equity
$99.46M
Working capital
$98.76M
Debt to equity
0.01
Current ratio
15.38
Quick ratio
15.04
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.5%
Return on equity
-58.4%
Return on invested capital
-76.1%
Return on capital employed
-47.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRVI stock price
How has the Trevi Therapeutics stock price performed over time
Intraday
-1.3%
1 week
-13.74%
1 month
-5.65%
1 year
119.86%
YTD
47.82%
QTD
-3.18%
Financial performance
How have Trevi Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.09M
Net income
-$47.35M
Gross margin
N/A
Net margin
N/A
Trevi Therapeutics's net income has decreased by 41% YoY
The operating income has contracted by 34% YoY
Price vs fundamentals
How does TRVI's price correlate with its fundamentals
Growth
What is Trevi Therapeutics's growth rate over time
Valuation
What is Trevi Therapeutics stock price valuation
P/E
N/A
P/B
5.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 32% YoY but it has increased by 4.3% QoQ
The P/B is 137% above the 5-year quarterly average of 2.5 and 44% above the last 4 quarters average of 4.1
The equity rose by 37% year-on-year
Efficiency
How efficient is Trevi Therapeutics business performance
Trevi Therapeutics's return on invested capital has decreased by 50% YoY but it has increased by 9% QoQ
Trevi Therapeutics's return on equity has decreased by 48% YoY but it has increased by 9% QoQ
TRVI's ROA is down by 43% YoY but it is up by 9% from the previous quarter
Dividends
What is TRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRVI.
Financial health
How did Trevi Therapeutics financials performed over time
TRVI's current ratio is up by 48% since the previous quarter and by 6% year-on-year
Trevi Therapeutics's quick ratio has increased by 47% QoQ and by 9% YoY
Trevi Therapeutics's debt is 99% less than its equity
TRVI's debt to equity has dropped by 50% year-on-year
The equity rose by 37% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.